Navigation Links
OGI invests in drug discovery at InDanio Bioscience
Date:10/19/2010

The InDanio screening system can be used, for example, to functionally characterize 'orphan' receptors those for which their natural ligands or specific function are unknown and thus qualify them as potential targets for drug discovery. The system can also be used to screen compound libraries in order to identify and refine potential new drugs that target NR proteins.

NRs are found inside cells and are responsible for sensing the presence of hormones and other molecules. They regulate the expression in the cell of a number of genes involved in homeostatic, metabolic and reproductive processes. NRs regulate the expression in the cell of a number of processes, and they also represent an important and successful class of drug targets implicated in some of the most prevalent diseases, including immune disorders, obesity, diabetes and cancer. A study four years ago determined that one seventh of drugs approved by the U.S. Food and Drug Administration (FDA) target nuclear receptors, and the top ten selling NR-based drugs combined represent worldwide annual sales of over USD $16 billion. Although many NRs have been targeted successfully, most of them have not been, and one third of them are still orphans.

InDanio was founded by Dr. Henry Krause, a professor in the Banting and Best Department of Medical Research at the University of Toronto, and Dr. Jens Tiefenbach, a post-doctoral fellow working with Dr. Krause and is based on the IP portfolio generated by their research.

"The OGI investment will allow InDanio to characterize the function of ill-understood members of the NR family and thus form the basis for establishing commercial partnerships to further characterize such receptors and develop drugs targeting them," commented Dr. Paul Chipperton, member of the InDanio board of directors and CEO of Profound Medical. "With a more efficient and comprehensive approach to probing the NR receptors, there is a tremendous opportunity to develop new therapeutic avenues into the NR family."

InDanio's zebrafish ligand trap (LT) technology and LT drug discovery platform will take advantage of the fact that zebrafish are transparent in early stages of development, thus allowing for the use of fluorescent protein markers. Many drugs never reach the marketplace because they fail toxicology tests or have other unintended effects on the body. Currently, in vitro testing relies on measuring simple chemical interactions to gauge a drug's effectiveness, but this is often not an effective predictor of how drugs will affect living organisms. By beginning the screening process with in vivo assays using live zebrafish, more information on a drug's effectiveness, toxicology and other side-effects can be gathered in advance of and to better inform downstream clinical trials.

"InDanio is in an excellent position to capitalize on the significant work undertaken by the academic and pharma sectors over the past 20 years in characterizing NR proteins and developing compound libraries targeting these proteins," commented Dr. Christian Burks, President and CEO of OGI. "Their screening system should provide novel, productive information on natural ligands, tissue and developmental specificity of natural or xenobiotic compounds, and whether or not a compound binds multiple receptors."


'/>"/>

Contact: Alastair Harris-Cartwright
aharriscartwright@ontariogenomics.ca
416-673-6582
Ontario Genomics Institute
Source:Eurekalert

Related biology news :

1. JPMorgan Chase & Co., Invests $25,000 to Support Bring Me A Books San Jose Elementary School Library Initiative
2. Finland invests €1.85 million in pan-European infrastructure for biomedical research
3. University of Plymouth invests in dental research
4. NIGMS invests in scientific Grand Opportunities with Recovery Act funds
5. Texas invests record $3.5 million in startup cofounded by UTs Mauro Ferrari
6. T cell discovery shows promise for Type 1 diabetes treatment: UBC-CFRI study
7. Research breakthrough hailed on the anniversary of gene discovery
8. Discovery of a cell that suppresses the immune system
9. Census of Marine Life celebrates decade of discovery
10. Discovery of key pathway interaction may lead to therapies that aid brain growth and repair
11. Biofuel from inedible plant material easier to produce following enzyme discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and ... rebranding initiative announced today. The bold new look is part of a transformation ... moves into a significant growth period. , It will also expand its service offering ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... Dr. Bob ... at his local San Diego Rotary Club. The event entitled “Stem ... CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... optimization firm for the life sciences and healthcare industries, announces a presentation by ... Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present ...
Breaking Biology Technology: